Compare BIO-TECHNE Corp (TECH) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs State Street Technology Select Sector SPDR ETF — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while State Street Technology Select Sector SPDR ETF trades at $188. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while State Street Technology Select Sector SPDR ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, State Street Technology Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals.
| TECH | XLK | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Sector/Thematic |
52-Week High | $72.48 | $198.21 |
52-Week Low | $43.31 | $127.49 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
XLK trades at $187.87, up 0.3% today, with a bullish technical signal from moving averages and support at $185. The ETF holds a concentrated mega-cap tech strategy with a low 0.08% expense ratio, though key financial ratios are unavailable. Recent news highlights sector inflows and AI-driven software shifts.
Outlook is supported by tech sector momentum and AI adoption, but risks include high concentration in top holdings and valuation sensitivity. Analysts favor XLK for its cost efficiency and exposure to AI growth, yet investors face volatility from economic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
